Stevanato Group SpA
NYSE:STVN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Stevanato Group SpA
NYSE:STVN
|
IT |
Stevanato Group SpA
Stevanato Group SpA, a stalwart in the realm of pharmaceutical and healthcare solutions, has carved its niche as a pioneering force in precision glass packaging and integrated drug delivery systems. founded in 1949 in Italy, the company ingeniously combines its deep-rooted expertise in glass manufacturing with cutting-edge technology to meet the burgeoning demands of the healthcare and pharmaceutical sectors. Stevanato’s operations are deftly structured around two main segments: the pharmaceutical systems division and the engineering division. Through its pharmaceutical systems division, the company crafts highly specialized glass vials, syringes, and cartridges critical for ensuring the safety and efficacy of drug delivery. These glass containers are not mere vessels but are integral to preserving the integrity of high-value biologic drugs, a prerequisite for gaining regulatory approval and market success.
Reaping the benefits of a vertically integrated business model, Stevanato’s engineering division complements its offerings by designing, developing, and manufacturing machinery and technology that optimize the production and inspection of its glass products. This segment caters to pharmaceutical companies' needs for enhanced reliability and efficiency in manufacturing processes, enabling Stevanato to cover the entire value chain from raw material sourcing to final packaging inspection. This seamless integration not only fortifies the company's market position but also ensures a robust revenue stream from both products and services. Stevanato Group's commitment to innovation and quality control, coupled with strategic collaborations, have propelled it as an indispensable partner to global pharmaceutical giants, anchoring its role as both a defender of drug integrity and a trailblazer in medical glassware innovation.
Stevanato Group SpA, a stalwart in the realm of pharmaceutical and healthcare solutions, has carved its niche as a pioneering force in precision glass packaging and integrated drug delivery systems. founded in 1949 in Italy, the company ingeniously combines its deep-rooted expertise in glass manufacturing with cutting-edge technology to meet the burgeoning demands of the healthcare and pharmaceutical sectors. Stevanato’s operations are deftly structured around two main segments: the pharmaceutical systems division and the engineering division. Through its pharmaceutical systems division, the company crafts highly specialized glass vials, syringes, and cartridges critical for ensuring the safety and efficacy of drug delivery. These glass containers are not mere vessels but are integral to preserving the integrity of high-value biologic drugs, a prerequisite for gaining regulatory approval and market success.
Reaping the benefits of a vertically integrated business model, Stevanato’s engineering division complements its offerings by designing, developing, and manufacturing machinery and technology that optimize the production and inspection of its glass products. This segment caters to pharmaceutical companies' needs for enhanced reliability and efficiency in manufacturing processes, enabling Stevanato to cover the entire value chain from raw material sourcing to final packaging inspection. This seamless integration not only fortifies the company's market position but also ensures a robust revenue stream from both products and services. Stevanato Group's commitment to innovation and quality control, coupled with strategic collaborations, have propelled it as an indispensable partner to global pharmaceutical giants, anchoring its role as both a defender of drug integrity and a trailblazer in medical glassware innovation.
Revenue: Q4 total company revenue was $346.5 million; full-year 2025 revenue grew 9% at constant currency and 7% reported vs 2024.
High-value momentum: High-value solutions saw strong growth—EUR 171 million in Q4 (up 31% YoY) and +29% in FY 2025—driving margin expansion.
GLP-1s: GLP-1 related revenue was ~19%–20% of company revenue in 2025, up >50% YoY; management expects mid‑teens growth for GLP‑1s in 2026.
Guidance: 2026 revenue guidance EUR 1.260–1.290 billion (EUR 1.278–1.308 billion constant currency); adjusted EBITDA EUR 331.8–346.9 million; adjusted diluted EPS EUR 0.59–0.63.
Segments: BDS grew double digits and offset a 23% Q4 decline in Engineering; Engineering is expected to decline mid-single to low double digits in 2026.
Margins & cash: Q4 gross margin 30.9% (up 120 bps); operating margin 20.2%; FY 2025 free cash flow EUR 18.4 million; 2026 modeled breakeven to ~EUR 20 million FCF.
Capacity & investment: Heavy 2025 investment (CapEx EUR 294.9 million) to expand high-value capacity (Latina, Fishers); net CapEx guide for 2026 EUR 240–260 million.
Risks/headwinds: Foreign exchange is a headwind (≈EUR 18 million in 2026, ≈EUR 10 million hit in Q1) and tariffs had limited but measurable impacts.
